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Clinical Medicine and Surgery, Federico II UnivAbstract Background and aims: Lipid oversupply to cardiomyocytes or decreased utilization of
lipids leads to cardiac steatosis. We aimed to examine the role of different circulating metabolic
biomarkers as predictors of myocardial triglyceride (TG) content in non-diabetic men.
Methods and results: Myocardial and hepatic TG contents were measured with 1.5 T magnetic
resonance (MR) spectroscopy, and LV function, visceral adipose tissue (VAT), abdominal subcu-
taneous tissue (SAT), epicardial and pericardial fat by MR imaging in 76 non-diabetic men. Serum
concentration of circulating metabolic biomarkers [adiponectin, leptin, adipocyte-fatty acid
binding protein 4 (A-FABP 4), resistin, and lipocalin-2] including b-hydroxybuturate (b-OHB)
were measured. Subjects were stratified by tertiles of myocardial TG into low, moderate, and
high myocardial TG content groups. Concentrations of b-OHB were lower (p Z 0.003) and serum
levels of A-FABP 4 were higher (p < 0.001) in the group with high myocardial TG content
compared with the group with lowmyocardial TG content. b-OHB was negatively correlated with
myocardial TG content (r Z 0.316, p Z 0.006), whereas A-FABP 4 was not correlated with
myocardial TG content (r Z 0.192, p Z 0.103). In multivariable analyses b-OHB and plasma
glucose levels were the best predictors of myocardial TG content independently of VAT and he-
patic TG content. The model explained 58.8% of the variance in myocardial TG content.
Conclusion: Our data showed that b-OHB and fasting glucose were the best predictors of myocar-
dial TG content in non-diabetic men. These data suggest that hyperglycemia and alterations in
lipid oxidation may be associated with cardiac steatosis in humans.
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Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. All rights reserved.ty acid binding protein; b-OHB, b-hydroxybuturate; CVD, cardiovascular disease; FFA, free fatty acid;
eostasis model assessment index; LV, left ventricular; MRS, magnetic resonance spectroscopy;
triglyceride; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.
g Center, Cardiology, Helsinki University Hospital, Haartmaninkatu 4, FIN-00290 HUH, Finland. Tel.: þ358 50
M. Granér).
etology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of
ersity. Published by Elsevier B.V. All rights reserved.
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Intramyocardial triglyceride (TG) content has been re-
ported to be higher in obesity [1], in subjects with the
metabolic syndrome [2], impaired glucose tolerance [3],
and in type 2 diabetes mellitus (T2DM) [4,5], suggesting
that cardiac steatosis is relatively common in humans.
Furthermore, increases in intramyocardial TG levels pre-
cede the development of cardiac dysfunction, suggesting a
causative role of myocardial fat in the development of
cardiac dysfunction in these disorders [5,6].
Adipose tissue, apart from its traditional role as en-
ergy storage, acts as a source for the production of
multiple bioactive molecules including adipokines. These
have important roles in the regulation of angiogenesis,
blood pressure, glucose homeostasis, lipid metabolism,
and vascular haemostasis [7]. The secretion of these
molecules is altered in adipose tissue dysfunction that
has consequences on vascular health and also cardiac
function.
Adipocyte-fatty acid binding protein (A-FABP), leptin,
resistin, and lipocalin-2, possess proinflammatory prop-
erties, whereas others, such as adiponectin, have an anti-
inflammatory effect [8]. A-FABP and adiponectin are the
two most abundant adipokines produced by adipocytes. A-
FABP 4, a member of FABP family, is a carrier protein that
facilitates intracellular FA trafficking from cell membranes
to lipid droplets or mitochondria in adipocytes and mac-
rophages. A-FABP 4 has been associated with levels of
adiposity, the metabolic syndrome, non-alcoholic fatty
liver disease, endothelial dysfunction, atherosclerosis, and
cardiovascular disease (CVD) mortality [9].
Limited information exists on the links between
adipocyte derived metabolic biomarkers and ectopic fat
accumulation in the heart assessed by magnetic resonance
spectroscopy (MRS) or magnetic resonance imaging (MRI).
Adiponectin has been inversely related with hepatic TG
content [10,11], myocardial TG content, epicardial and
pericardial fat depots [3,12]. Leptin has been associated
with the soleus intramyocellular lipid content [10].
Ketone bodies serve as important energy sources to
cardiac and skeletal muscle and nervous tissue during
fasting state. b-hydroxybuturate (b-OHB) belongs to the
group of ketone bodies and is formed during FA oxidation
by reduction of acetoacetate in the liver. Prolonged expo-
sure to b-OHB has shown to inhibit insulin-stimulated
glucose uptake in adult rat cardiomyocytes [13]. In
humans, lower basal b-OHB concentrations have been
found in obese than in lean individuals [14,15] and in pa-
tients with non-alcoholic fatty liver disease [16].
The purpose of the current study was to determine
differences in the concentration of different circulating
biomarkers potentially modifying lipid and energy ho-
meostasis with increasing amount of intramyocardial TG
in a large non-diabetic group of men free of CVD. Our
second objective was to examine the association of
different biomarkers with different ectopic fat depots. We
also evaluated the independent predictors of myocardial
TG content.Methods
Study population
A total of 77 men were examined using the same study
cohort as have been previously described [2]. A detailed
description of the study recruitment can be found in
Supplemental Material. Briefly, the subjects were catego-
rized into tertiles based on myocardial TG content: group 1
(n Z 25) Z myocardial TG low, group 2
(n Z 26) Z myocardial TG moderate, and group 3
(nZ 25)Zmyocardial TG high. One subject in the group 2
was excluded and considered as outlier due to a highly
elevated serum b-OHB concentration. Thirty-seven par-
ticipants fulfilled the criteria for the metabolic syndrome
[17]. In these participants, myocardial ischemia was
excluded by means of adenosine stress MR perfusion test.
The study was approved by the Helsinki University Central
Hospital Ethics Committee and conforms to the principles
outlined in the Declaration of Helsinki. Each subject pro-
vided written informed consent.
Demographic variables and biochemical investigations
Waist circumference was determined midway between
iliac crest and the lower rib margin. Blood pressure was
measured by BPM-200 (Quick Medical, WA, USA) in the
sitting position after a 5 min rest, and the mean of five
measurements was recorded. The subjects were classified
as present, past or non-smokers.
Blood samples were collected after overnight fasting.
Total serumcholesterol, TGs, very low-density, high-density
lipoprotein cholesterol, FFAs, apolipoprotein B, and high-
sensitivity C-reactive protein were analyzed as previously
described [2]. The concentration of low-density lipoprotein
cholesterol was calculated using the Friedewald formula
[18]. Fasting and postload glucose were determined by the
hexokinase method (Roche Diagnostic Gluco-quant) using
either a Hitachi 917 or a Modular analyzer (Hitachi Ltd,
Tokyo, Japan). Serum insulin concentrationwas assessed by
double-antibody radioimmunoassay (Pharmacia RIA kit,
Pharmacia, Uppsala, Sweden). The insulin-resistance ho-
meostasis model assessment (HOMA-IR) index was calcu-
latedusing the following formula: (fastingplasmaglucose
fasting plasma insulin)/22.5 [19].
We used commercially available enzyme-linked
immunosorbent assays for measuring serum levels of
adiponectin (R&D Systems, Minneapolis, MN, USA), leptin,
resistin (Mediagnost, Reutlingen, Germany), A-FABP 4
(Biovendor, Brno, Czech Republic), and lipocalin-2 (R&D
Systems), according to the manufacturer’s protocol. Serum
b-OHB concentration was determined enzymatically
(DiaSys Diagnostic Systems, Holzheim, Germany).
Determination of myocardial and hepatic triglyceride
content
Myocardial and hepatic TG content were measured by 1H-
MRS with a 1.5 T (MAGNETOM Avanto; Siemens AG,
136 M. Granér et al.Erlangen, Germany) whole-body MR imager as previously
described [2]. Details on measurement of myocardial and
hepatic TG content are reported in Supplemental Material.Left ventricular analysis and determination of adipose
tissue volumes
Cardiac imaging was performed with a 1.5 T whole-body
MR imager (MAGNETOM Avanto; Siemens AG, Erlangen,
Germany) as previously described [2]. Volumetric analysis
of the LV was scrutinized using dedicated post-processing
software (Argus, Siemens). LV ejection fraction and mass
were reported, and mass was indexed to subject’s body
surface area and height2.7.
The distributions of VAT and subcutaneous adipose
tissue (SAT) were determined as previously described [2].
We calculated the VAT/SAT ratio as a metric of abdominal
fat distribution [20]. Epicardial and pericardial fat were
measured as previously described [2].Table 1 Clinical and biochemical characteristics, ectopic fat deposits, and
content.
Myocardial TG co
low (n Z 25)
Myocardial triglyceride content (%) 0.32 (0.14e0.45)
Age (years) 39  7
Body mass index (kg/m2) 23.4 (17.6e38.5)
Waist circumference (cm) 85.5 (71.0e129.0)
Systolic blood pressure (mmHg) 111 (98e152)
Diastolic blood pressure (mmHg) 73 (61e90)
Current smokers (N, %) 1 (4)
Total cholesterol (mmol/L) 4.26  0.85
Very low-density lipoprotein cholesterol (mmol/L) 0.39 (0.07e2.77)
Low-density lipoprotein cholesterol (mmol/L) 2.42  0.67
High-density lipoprotein cholesterol (mmol/L) 1.39  0.41
Triglycerides (mmol/L) 0.73 (0.35e3.47)
Apolipoprotein B (mg/dL) 74  22
High-sensitivity C-reactive protein (mg/L) 0.3 (0.0e9.3)
Fasting free fatty acids (mmol/L) 447  231
Fasting plasma glucose (mmol/L) 5.0 (4.5e6.7)
Fasting serum insulin (mU/L) 2.9 (0.9e22.3)
HOMA-IR index 0.6 (0.2e6.6)
Epicardial fat (mm2) 494 (283e1666)
Pericardial fat (mm2) 497 (118e2649)
Hepatic triglyceride content (%) 0.70 (0.17e21.69)
VAT (cm3) 571 (67e5061)
SAT (cm3) 1443 (284e9188)
VAT/SAT ratio 0.42 (0.14e1.09)
LV ejection fraction (%) 62  3
LV mass (g) 122  14
LV mass/Body surface are (g/m2) 62  6
LV mass/height2.7 26  4
Data are expressed as means (SD), medians (range) or as frequencies (%)
left ventricular; SAT, subcutaneous adipose tissue; TG, triglyceride; VAT, v
P-values for analysis of variance between myocardial TG content groups,
a Analysis of variance based on log-transformed values in order to assu
b Differs significantly (p < 0.05) from myocardial TG content group low
c Differs significantly (p < 0.05) from myocardial TG content group mo
d P-value based on c 2-test.Statistical analyses
All statistical analyses were performed with SPSS 22 for
Windows (SPSS, Inc., Chicago, Illinois).
Logarithmic transformations of skewed variables were
performed before analysis in order to achieve an approx-
imately normal distribution, when necessary. Data are
presented as frequencies or percentages for categorical
variables, as means  SD for approximately normally
distributed continuous variables, and as medians (range)
for skewed variables. Between-group differences for the
metabolic biomarkers were examined by one-way analysis
of variance and p-values for pairwise between groups
difference were adjusted for multiple comparison in a post
hoc Bonferroni method. Correlations were calculated by
the partial correlations coefficients after accounting for age
and body mass index. Multivariable regression analyses
were used to evaluate the impact of different metabolic
biomarkers on myocardial TG content. The final model was
decided using the stepwise linear regression procedure,left mass and function across tertiles of myocardial triglyceride (TG)
ntent Myocardial TG content
moderate (n Z 26)
Myocardial TG
content high (n Z 25)
P
0.74 (0.46e0.87)b 1.29 (0.88e2.33)b <0.001a
45  7b 46  7b 0.032
26.6 (22.5e38.6)b 30.6 (21.8e42.5)b <0.001a
97.5 (78.5e125.0)b 107.0 (82.5e135.0)b <0.001a
124 (101e153)b 128 (99e183)b 0.012a
85 (69e110)b 82 (69e119)b <0.001a
4 (15) 13 (52)c <0.001d
5.05  0.79b 5.10  0.73b 0.001
0.70 (0.21e4.65)b 1.45 (0.27e3.15)b <0.001a
3.14  0.79b 3.07  0.66b 0.024
1.25  0.33 1.13  0.42 <0.001
1.11 (0.55e5.13)b 2.20 (0.54e6.26)b <0.001a
99  28b 109  29b <0.001
0.5 (0.0e5.1) 1.6 (0.0e11.8) 0.422a
479  147 517  178 1.000
5.3 (4.4e6.4) 5.8 (4.8e6.9)b 0.013a
5.9 (1.5e22.5) 7.8 (1.9e36.9)b <0.001a
1.5 (0.3e5.1)b 2.0 (0.4e8.0)b <0.001a
695 (373e1753)b 838 (295e1666)b <0.001a
1121 (66e6131)b 1582 (266e4631)b <0.001a
2.37 (0.27e22.01)b 6.72 (0.44e31.74)b <0.001a
2272 (140e4935)b 3304 (350e5743)b <0.001a
2952 (1103e8802)b 4663 (871e9354)b <0.001a
0.60 (0.13e1.55) 0.58 (0.21e1.64) 0.300a
61  5 62  6 1.000a
120  17 134  22 0.317
57  9 62  9 0.500
24  4 27  4c 0.107
. HOMA-IR, the homeostasis model assessment insulin resistance; LV,
isceral adipose tissue.
all p-values Bonferroni adjusted for multiple testing.
re the assumption of normally distributed residuals.
. Tests are Bonferroni adjusted for multiple comparisons.
derate. Tests are Bonferroni adjusted for multiple comparisons.
Table 2 Biomarkers across tertiles of myocardial triglyceride (TG) content.
Myocardial TG content low
0.32 (0.14e0.45)
(n Z 25)
Myocardial TG content moderate
0.74 (0.46e0.87)
(n Z 26)




S-Adiponectin (ug/mL) 2.54 (0.56e6.83) 1.80 (0.20e5.56) 1.12 (0.59e3.85)b 0.125a
S-Leptin (ng/mL) 1.26 (0.01e25.65) 6.38 (1.07e30.54) 8.70 (0.01e30.23) 0.092
S-A-FABP 4 (ng/mL) 7.73 (4.72e21.27) 16.28 (7.48e30.81)b 17.22 (7.23e52.33)b <0.001a
S-b-OHB (mg/dL) 1.02 (0.51e4.56) 0.67 (0.46e3.98)b 0.68 (0.27e4.89)b 0.003a
S-Resistin (ng/mL) 3.03  0.87 3.14  0.86 2.76  0.72 0.200
S-Lipocalin-2 (ng/mL) 60.66  15.88 64.25  13.67 58.02  14.44 0.112a
Data are expressed as means (SD) or medians (range). A-FABP, adipocyte-fatty acid binding protein; OHB, hydroxybutyrate; TG, triglyceride.
P-values for analysis of variance between myocardial TG content groups adjusted for age and body mass index.
a Analysis of variance based on log-transformed values in order to assure the assumption of normally distributed residuals.
b Differs significantly (p < 0.05) from myocardial TG content group low. Tests are Bonferroni adjusted for multiple comparisons.
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permanent predictors in the model. The permanent pre-
dictors were always included, and not subjects for exclu-
sion during the stepwise procedure. To avoid
multicollinearity, parameters of glucose tolerance were
not forced into the same model. A p value <0.05 was
considered statistically significant.Results
Data on clinical and biochemical characteristics, body
composition, and LV mass and function in men with low,
moderate, and high myocardial TG content are given in
Table 1. Subjects with high or moderate myocardial TG
content were older, had higher body mass index, waist
circumference, systolic and diastolic blood pressures
compared with the group with low myocardial TG content.
There were a larger number of current smokers in the high
and moderate myocardial TG content groups compared to
the low myocardial TG group. The average levels of total
cholesterol, low-density lipoprotein cholesterol, TGs,
apolipoprotein B, fasting glucose, insulin, and HOMA-IR
increased with increasing myocardial TG content. High-Table 3 Results of stepwise multivariable regression analyses.
Independent variables Myocardial TG content (log)
Unstandardized coefficients
b Std. Error p
Constant 8.468 1.759 <0.001
Age (log) 0.765 0.296 0.012
Body mass index (log) 0.493 0.446 0.273
Triglyceride (log) 0.095 0.117 0.423
fP-glucose (log) 1.711 0.561 0.003
Smoking status 0.258 0.122 0.039
S-Adiponectin (log) 0.169 0.081 0.042
S-Adipocyte fatty-acid
binding protein 4 (log)
0.268 0.140 0.060
B-hydroxy buturate (log) 0.256 0.080 0.002
Adjusted R2 0.588 <0.001
Age, body mass index, smoking status, and triglycerides included as
permanent predictors in the model.density lipoprotein cholesterol decreased with increasing
myocardial TG content [Table 1].
Epicardial and pericardial fat were higher in the groups
with high and moderate myocardial TG content compared
with the group with low myocardial TG content. In sub-
jects with high myocardial TG content the hepatic TG
content (range 0.44e31.74) was w10-fold higher than in
those with low myocardial TG content. Similarly, VAT and
SAT were significantly higher in the groups with high
myocardial TG content compared with the group with low
myocardial TG content. The VAT/SAT ratio was comparable
between the study groups [Table 1].
Serum concentrations of biomarkers in the study pop-
ulation divided according to myocardial TG content are
presented in Table 2. b-OHB was significantly higher in
subjects with low myocardial TG content compared with
individuals with high myocardial TG content. A-FABP4
serum levels were higher in the group with high myocar-
dial TG content compared to the group with low myocar-
dial TG content. Leptin levels were higher in subjects with
high myocardial TG content compared to subjects with low
myocardial TG content but did not reach statistical sig-
nificance. Concentrations of adiponectin, resistin, and
lipocalin-2 were comparable between the study groups
(Table 2).
In unadjusted correlation analyses concentrations of b-
OHB and adiponectin were negatively correlated with
myocardial TG content (r Z 0.313, p Z 0.006 and
r Z 0.480, p < 0.001, respectively). A-FABP 4 was
strongly correlated with myocardial TG content (r Z 0.607,
p < 0.001).
Age- and body mass index-adjusted correlation ana-
lyses revealed that b-OHB and adiponectin remained
negatively associated with myocardial TG content, but A-
FABP 4 did not correlate with myocardial TG content.
Adiponectin was negatively associated with hepatic TG
content, pericardial fat, and VAT. Serum leptin levels were
correlated with epicardial fat, VAT, and SAT. A-FABP 4
serum levels were associated with SAT. b-OHB was nega-
tively correlated with VAT. In addition, adiponectin was
negatively correlated with TGs. Levels of leptin, A-FABP 4,
and resistin were positively correlated with insulin and
Table 4 Results of stepwise multivariable regression model from
Table 3, but with visceral adipose tissue included in the model.
Independent variables Myocardial TG content (log)
Unstandardized coefficients
b Std. Error p
Constant 8.175 1.853 <0.001
Age (log) 0.714 0.313 0.026
Body mass index (log) 0.405 0.477 0.400
Triglyceride (log) 0.099 0.118 0.404
fP-glucose (log) 1.648 0.576 0.006
Smoking status 0.257 0.123 0.041
S-Adiponectin (log) 0.161 0.083 0.057
S-Adipocyte fatty-acid
binding protein 4 (log)
0.238 0.151 0.120
B-hydroxy buturate (log) 0.249 0.082 0.003
Visceral adipose tissue (log) 0.050 0.095 0.597
Adjusted R2 0.584 <0.001
Age, body mass index, smoking status, and triglycerides included as
permanent predictors in the model.
138 M. Granér et al.HOMA-IR. b-OHB showed a strong correlation with FFAs
(Supplemental Table 1).
Finally, we performed a multivariable regression anal-
ysis to further evaluate independent determinants of
myocardial TG content. The regression model included all
six biomarkers in Table 2 as well as potential confounders
(Table 3). This full model had an adjusted explanatory
factor of 0.588, i.e. after adjusting for the number of pre-
dictors the model explained 58.8% of the variance in
myocardial TG content. The model showed age, fasting
glucose, smoking status, adiponectin, and b-OHB to be
significant independent determinants for myocardial TG
content. The model also showed borderline significance for
the A-FABP 4. The outcome was closely similar when VAT
was included in the full model (Table 4) and when VAT
was replaced by hepatic TG content (data not shown).
Fasting insulin and HOMA-IR were not significant pre-
dictors of myocardial TG content (see Supplemental Tables
2 and 3).Discussion
This study showed, in a large cohort of non-diabetic men
free of CVD, that b-OHB was significantly lower and A-
FABP 4 higher in subjects with high myocardial TG content
compared to individuals with low myocardial TG content.
In addition, b-OHB was negatively correlated with
myocardial TG content, whereas A-FABP 4 was not corre-
lated with myocardial TG content. In multivariable ana-
lyses b-OHB and plasma glucose levels were the best
predictors of myocardial TG content even beyond VAT and
hepatic TG content.
In a normal heart, constant energy supply is primarily
met by the b-oxidation of long-chain FAs. b-oxidation
accounts for about 50e70% of the energy production of
the heart, with the remainder primarily accounted for by
carbohydrate (glucose and lactate) oxidation, and the
oxidation of ketone bodies [21]. Within the heart, therenormally is little intramyocardial lipid accumulation,
suggesting that the uptake and oxidation of FFAs is finely
regulated. Overall, the cardiac TG pool is not inert, but
rather depends on, and responds dynamically to, the
intracellular fluxes of FAs. There are two possible sce-
narios to explain the accumulation of intramyocardial TG:
1) oversupply of FAs, and 2) impaired FA oxidation. A
number of factors, including insulin resistance, contribute
to high levels of circulating FAs [22]. Recently another
major source of FAs for cardiomyocytes has been reported
to be circulating TG-rich lipoproteins hydrolyzed by li-
poprotein lipase in the heart [23]. A key regulatory step is
the uptake of FFA into cardiomyocytes mediated by FABPs
and tissue specific fatty acid transporter proteins, CD36/
FAT, and subsequent esterification of FAs. Cardiac insulin
resistance is accompanied by a persistent relocation of the
fatty acid transporters CD36 and FABP from the cytosol to
the cell membrane [22]. Persistent relocation of FA
transporters leads to a chronic elevation in FA uptake,
which could contribute to the increased FA oxidation
observed in diabetic hearts [22]. Genetic studies also
indicate a role for proteins involved in FA uptake playing a
role in the progression of diabetic cardiomyopathy [22].
We report here that A-FABP 4 serum levels were higher in
the group with high myocardial TG content compared to
the group with low myocardial TG content. However, A-
FABP 4 did not reach significance in the multivariate
analyses.
Increasing FA oxidation in the heart downregulates
glucose oxidation, while increasing glucose oxidation in-
hibits FA oxidation. In obese or diabetic heart an elevation
of circulating FA is associated with myocardial insulin
resistance, and the utilization of excess FA can lead to an
impaired consumption of glucose [22]. Furthermore, in
the diseased heart glucose uptake rates are elevated, due
to hyperinsulinemia and the heart’s ability to remain
insulin-sensitive [24]. In line with previous reports [2,3]
we showed that hyperglycemia was linked to cardiac
steatosis. Interestingly, data from recent animal study [25]
indicate that hyperglycemia increases myocardial glucose
uptake by glucose mass action independently of insulin.
Notably, in a recent study including subjects with and
without the metabolic syndrome, myocardial steatosis
was unrelated to antilipolytic and glucoregulatory actions
of insulin [26]. Likewise, our data suggests that insulin
resistance is not an independent determinant of cardiac
steatosis.
Three compounds are grouped together as ketone
bodies: acetoacetate, b-OHB, and acetone. Circulating
levels of ketones depend on both the rate of their pro-
duction by the liver and their use by extrahepatic tissue.
The rate of production of b-OHB is dependent on the fluxes
of plasma FFA into the liver and is correlated with the rate
of lipid oxidation and therefore is considered to be a sur-
rogate marker of lipid oxidation [27]. In the present study,
the concentration of b-OHB was unexpectedly significantly
lower in subjects with high myocardial TG content but the
concentrations of plasma FFA were not reduced indicating
disturbed metabolic regulation of ketone bodies.
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sources to nervous tissue, skeletal and cardiac muscle.
Cardiomyocytes oxidize ketone bodies in proportion to
their delivery, at the expense of terminal FA oxidation and
glucose oxidation as ketone body oxidation is energetically
more efficient than terminal FA oxidation [27]. In humans,
lower basal b-OHB concentrations have been found in
obese than in lean individuals [14,15] and in patients with
non-alcoholic fatty liver disease [16]. To our knowledge
this has not been previously reported in subjects with
excess of myocardial TG content. We also demonstrate an
inverse relationship between b-OHB and myocardial TG
content. Altogether, our data suggest that myocardial ke-
tone body oxidation may be increased in cardiomyocytes
as an adaptive mechanism at the expense of energy shifts
between lipid and glucose oxidations in subjects with
increased myocardial TG content. Whether this is true
remains to be established in positron emission tomogra-
phy studies in a clinical setting.
This study provided the opportunity to evaluate the
relationship between different adipocyte derived meta-
bolic biomarkers and ectopic fat accumulation. As ex-
pected, adiponectin levels declined across the study
groups, although the difference did not reach statistical
significance in age- and body mass index adjusted uni-
variate analysis. In line with previous studies [3,10e12], we
observed an inverse relationship between adiponectin and
the three fat depots of VAT, myocardial and hepatic TG
content. Moreover, in multivariable regression analyses
adiponectin was the only independent determinant of
myocardial TG content in our biomarker panel. Although
adiponectin has numerous beneficial effects on the arterial
wall, on the liver, as well as on insulin actions, its inde-
pendent contribution to the etiology of CVD remains
controversial [28].
Strengths of the work are that it was performed in a
large cohort of non-diabetic men free of CVD. Six different
ectopic fat depots were assessed noninvasively in a
quantitative fashion using 1H-MRS and MRI. Finally, this
study did not consider only one circulating metabolic
biomarker, but six biomarkers were simultaneously
assessed in an attempt to dissect out their relative
importance in predicting myocardial TG content.
On the other hand, we acknowledge some limitations of
the study. Both gender and age may influence the
magnitude of cardiac steatosis although the data are not
consistent [28,29]. Accordingly, only men were included in
this study and the data were adjusted to age. However,
increased myocardial TG content has also been reported in
insulin-resistant obese women [30]. Finally, as the study
design is cross-sectional the observational interferences of
causality remain limited.
In conclusion, b-OHB is reduced in non-diabetic men
with increasing amount of myocardial TG content. In
multivariable analyses b-OHB and plasma glucose levels
were the best predictor of myocardial TG content even
beyond VAT and hepatic TG content. This suggests that
reduced lipid oxidation and hyperglycemia may be impli-
cated in the pathogenesis of cardiac steatosis.Acknowledgments
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